Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 55

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 55
---
) the maturity date, or (y) if any note that has been called (or deemed called) for optional redemption or tax redemption is converted, the related optional redemption date or tax redemption date, then we will settle any such conversion on the maturity date (or, if the maturity date is not a business day, the next business day), or the related optional redemption date or tax redemption date, as applicable.

Each conversion will be deemed to have been effected as to any notes surrendered for conversion on the conversion date; provided , however , that the person in whose name the ADSs shall be deliverable upon such conversion will be treated as the holder of record of such shares as of the close of business on the conversion date.

#### Conversion Share Limitations
Notwithstanding anything to the contrary herein, under English law, we must obtain shareholder authority to allot ordinary shares or grant rights to subscribe for or convert any security into ordinary shares. In addition, English law generally provides shareholders with preemptive rights when equity securities are allotted (which includes the grant of a right to subscribe for or convert any security into ordinary shares) for cash; however, it is possible for the articles of association, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and voting at that general meeting, to disapply these preemptive rights. The number of ordinary shares represented by the ADSs deliverable upon conversion of the notes may not exceed the number of ordinary shares authorized by our shareholders to be issued and allotted by our board of directors, free from preemptive rights and not previously used by our board of directors (the “allotment share cap”).

On February 3, 2021, our shareholders authorized our directors, for a period up to the close of business on February 2, 2026 to issue ordinary shares and to grant rights to subscribe for or convert any security into ordinary shares, up to an aggregate nominal amount of £150,000 (equivalent to 75,000,000 ordinary shares) and disapplied statutory preemptive rights in respect of such issuances and grant of rights, and during this period we may make offers and enter agreements which would or might require shares to be issued or rights to be granted after the expiration of the period and the directors may issue shares or grant rights in pursuance of such offers or agreements as if the authority had not expired. As of February 28, 2025, £52,765.874 of aggregate nominal value of ordinary